For Immediate Assistance Call 1-800-966-2244
Mesothelioma News

Maryland Company Moving Forward With Testing of Mesothelioma Treatment

A Maryland-based life sciences company has reported positive results in the most recent phase of testing of its new mesothelioma medication, and will be moving forward with the next phase with high hopes. In conducting its Phase I clinical trial, MaxCyte is testing a higher dose of its proprietary mesothelin-targeting chimeric antigen receptor (CAR) therapy on a third cohort of patients diagnosed with peritoneal mesothelioma as well as with ovarian cancer.

The patients that the company’s treatment protocol targets are those who have ovarian cancer or peritoneal mesothelioma that is either relapsed or refractory, meaning that it is not responding to treatment. The second cohort, which was just completed, revealed that infusions of MCY-M11, administered intraperitoneally, were well tolerated in the patients on whom it was administered, with no infusion-related adverse events, toxicities or other unwanted impacts seen. The Phase I clinical trial is looking for the appropriate levels of effectiveness that will still be safe and tolerable.

Speaking of the success that they have seen thus far in mesothelioma patients, the company’s Chief Medical Officer Claudio Dansky Ullmann, MD said, “We are making significant progress with our lead CAR therapeutic and our proprietary CARMA autologous cell therapy platform. Furthermore, the on-going trial continues to demonstrate the feasibility of our one-day cell therapy manufacturing process. We are very excited about the potential of MCY-M11 as a new, effective therapeutic in solid tumors where the majority of patients still have very limited treatment options.” If it continues to be tested successfully, MCY-M11 will be used to treat platinum-resistant cancers of the ovaries, primary peritoneum and fallopian tube, as well as those diagnosed with advanced peritoneal mesothelioma that returns after chemotherapy. The tests are being conducted at the National Cancer Institute at the National Institutes of Health and at Washington University at St. Louis.

Mesothelioma victims look to researchers for aggressive treatment options and to the legal system for justice. If you have been diagnosed with malignant mesothelioma and you need information, contact us today at  1-800-966-2244.

Author: Terri Oppenheimer

Terri Oppenheimer

Terri Oppenheimer is an independent writer, editor, and proofreader. She graduated from the College of William and Mary with a degree in English. Her dreams of a writing career were diverted by a need to pay her bills. She spent a few years providing the copy for a major retailer, then landed a lucrative career in advertising sales. With college bills for all three of her kids paid, she left corporate America for a return to her original goal of writing. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of interest include health and fitness, medical research, and the law.